Rennes and Paris, September 17th, 2024 - VitaDX, an innovative player in the French deep tech sector, announces strategic changes to its organization with the appointment of Hilja Ibert and Sébastien Dias to its Board of Directors.
These appointments come at a key moment for VitaDX, as the company consolidates its position in the field of early cancer diagnosis, particularly bladder and thyroid cancer, thanks to its patented technology based on image processing and AI.
Strategic profiles dedicated to innovation
The integration of Hilja Ibert and Sébastien Dias to the Board of Directors represents a major strategic asset for VitaDX.
With their experience in diagnostics, medical devices and life sciences, they will help refine the company's vision, support its development and explore new growth opportunities.
Hilja Ibert brings over 30 years of experience in life sciences. She has held management roles at diagnostic industry leaders such as Hologic, Becton Dickinson and bioMérieux. Her expertise, acquired as CEO of miDiagnostics and Gentian Diagnostics, will considerably strengthen the international vision of VitaDX by guiding the company in its strategy and the positioning of its products in the diagnostic sector, a field that is both complex and demanding.
“Joining the VitaDx Board is a great honor for me. The AI-based product solutions from VitaDx enable the early detection of cancer, which is addressing a preeminent need of the global health care market. I am looking very much forward to the collaboration with Allan and his team during this exciting phase of the company.” Says Hilja Ibert.
Sébastien Dias, a medical doctor and graduate of HEC, is recognized for his expertise in corporate strategy and international development, which he developed through management positions at McKinsey, Novartis, Sanofi and in his role as General Manager at Becton Dickinson France. His vision, focused on innovation and operational excellence, will be an invaluable asset in supporting VitaDX in its next stages of development.
“I am honored to join the VitaDX Board of Directors at a key moment in its development. The company's technological innovation, based on artificial intelligence, has immense potential to improve the early diagnosis of cancer. I look forward to bringing my experience to support this growth dynamic and explore new avenues to broaden VitaDX's impact in the field of medical diagnostics.” Says Sébastien Dias.
Allan Rodriguez, co-founder and pillar of VitaDX since 2015, is now Chairman of the Board of Directors. His in-depth knowledge of the company and his commitment are a guarantee of continuity and vision for the company.
“We are immensely proud to welcome Hilja and Sébastien to the VitaDX Board of Directors. Their appointments represent a strategic turning point for our company. Their expertise and vision will enable us to strengthen our market position and accelerate our international growth” says Allan Rodriguez.
Leila Nicolas, GO Capital, a board member for several years, shares her enthusiasm:
“The arrival of Hilja and Sébastien on the board brings crucial expertise in the diagnostics field and gives us new perspectives to lead the development of VitaDx. Their experience will be essential in accelerating our growth. We look forward to collaborating and moving forward together.” Says Leila Nicolas.
VitaDX warmly thanks the outgoing members for their valuable contributions and enthusiastically welcomes Hilja Ibert and Sébastien Dias, whose expertise and vision will be invaluable assets for the company's future success.
With these changes, VitaDX reinforces its commitment to innovation in the medical diagnostics sector and to continued international expansion.
About VitaDX International
Founded in 2015, VitaDX develops and commercializes cancer diagnostic solutions that combine image analysis and artificial intelligence applied to cytology with its patented VisioCyt® technology. Its mission is to develop innovative, high-performance solutions with a significant impact on healthcare systems, benefiting the largest number of patients. After several years of development and a prospective multicenter clinical study, its first CE IVDR-marked solution, VisioCyt® Bladder, enables the diagnosis and monitoring of bladder cancer from a simple urine sample. Other devices are under development, including those for bladder cancer screening and thyroid cancer diagnosis.
For more information: www.vitadx.com
Contacts : VitaDX International : Lucie Paget – Marketing & Communications Manager - l.paget@vitadx.com - +33(0)7.67.12.62.78